Literature DB >> 12880508

Stimulant rebound: how common is it and what does it mean?

Gabrielle A Carlson1, Kevin L Kelly.   

Abstract

OBJECTIVE: To examine rates and implications of stimulant-induced rebound - the behavioral deterioration that may occur as stimulant medications wear off.
METHODS: This study compares nurse observations on evening shifts compared to day shifts in 149 psychiatrically hospitalized children treated with short-acting stimulants, usually methylphenidate, comparing nonmedication and stimulant-treated states.
RESULTS: Behavioral deterioration (rebound), was observed in 30% of children on at least one dose of stimulants but was serious enough to discontinue treatment in only 8.7%. Children experiencing rebound did not differ clinically from those who did not.
CONCLUSIONS: Rebound exists, occurs significantly in less than 10% of psychiatrically hospitalized children with attention deficit hyperactivity disorder, and does not appear to have specific diagnostic significance.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12880508     DOI: 10.1089/104454603322163853

Source DB:  PubMed          Journal:  J Child Adolesc Psychopharmacol        ISSN: 1044-5463            Impact factor:   2.576


  13 in total

1.  Executive function deficits in children with attention-deficit/hyperactivity disorder and improvement with lisdexamfetamine dimesylate in an open-label study.

Authors:  Atilla Turgay; Lawrence Ginsberg; Elias Sarkis; Rakesh Jain; Ben Adeyi; Joseph Gao; Bryan Dirks; Thomas Babcock; Brian Scheckner; Cynthia Richards; Robert Lasser; Robert L Findling
Journal:  J Child Adolesc Psychopharmacol       Date:  2010-12       Impact factor: 2.576

2.  The Dopamine Dilemma-Part II: Could Stimulants Cause Tolerance, Dependence, and Paradoxical Decompensation?

Authors:  Jason Yanofski
Journal:  Innov Clin Neurosci       Date:  2011-01

Review 3.  Abuse-deterrent and tamper-resistant opioid formulations: what is their role in addressing prescription opioid abuse?

Authors:  Jennifer P Schneider; Michele Matthews; Robert N Jamison
Journal:  CNS Drugs       Date:  2010-10       Impact factor: 5.749

Review 4.  Sleep problems in the child with attention-deficit hyperactivity disorder: defining aetiology and appropriate treatments.

Authors:  Margaret D Weiss; Jay Salpekar
Journal:  CNS Drugs       Date:  2010-10       Impact factor: 5.749

5.  Methylphenidate and emotional-motivational processing in attention-deficit/hyperactivity disorder.

Authors:  Annette Conzelmann; Eva Woidich; Ronald F Mucha; Peter Weyers; Mathias Müller; Klaus-Peter Lesch; Christian P Jacob; Paul Pauli
Journal:  J Neural Transm (Vienna)       Date:  2016-02-06       Impact factor: 3.575

6.  Dopamine transporter genotype and stimulant side effect factors in youth diagnosed with attention-deficit/hyperactivity disorder.

Authors:  Reut Gruber; Ridha Joober; Natalie Grizenko; Bennett L Leventhal; Edwin H Cook; Mark A Stein
Journal:  J Child Adolesc Psychopharmacol       Date:  2009-06       Impact factor: 2.576

7.  Effect of extended-release dexmethylphenidate and mixed amphetamine salts on sleep: a double-blind, randomized, crossover study in youth with attention-deficit hyperactivity disorder.

Authors:  J A Santisteban; M A Stein; L Bergmame; R Gruber
Journal:  CNS Drugs       Date:  2014-09       Impact factor: 5.749

8.  Psychotropic medication exposure and age at onset of bipolar disorder in offspring of parents with bipolar disorder.

Authors:  Kiki D Chang; Kirti Saxena; Meghan Howe; Diana Simeonova
Journal:  J Child Adolesc Psychopharmacol       Date:  2010-02       Impact factor: 2.576

9.  Stimulant Withdrawal in a Child with Autism Spectrum Disorder and ADHD - A Case Report.

Authors:  Aneta Krakowski; Abel Ickowicz
Journal:  J Can Acad Child Adolesc Psychiatry       Date:  2018-04-01

10.  Adult Patient Preferences for Long-Acting ADHD Treatments: A Discrete Choice Experiment.

Authors:  M Janelle Cambron-Mellott; Jaromir Mikl; Joana E Matos; Jennifer G Erensen; Kathleen Beusterien; Marc J Cataldo; Bernadette Hallissey; Gregory W Mattingly
Journal:  Patient Prefer Adherence       Date:  2021-05-21       Impact factor: 2.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.